Discover and read the best of Twitter Threads about #IDWeek22
Most recents (1)
ACTIV-1 infliximab, abatacept and cenicriviroc (CVC) as immunomodulators in COVID-19. Emily Ko
#IDWeek22
COVID-19 with pneumonitis / hypoxia
Primary endpoint - time to recovery
Ages 55, 60% male, BMI 32, 50% obese
Receiving remdesivir and steroids, <10% IMV
#IDWeek22
COVID-19 with pneumonitis / hypoxia
Primary endpoint - time to recovery
Ages 55, 60% male, BMI 32, 50% obese
Receiving remdesivir and steroids, <10% IMV
Infliximab - about 500 in active and placebo arms; no diff in time to recovery. 41% lower odds of day 28 mortality, 32% higher odds of clinical status at day 14.
No diff in adverse events
No diff in adverse events
Abatacept - about 500 in active and placebo; no diff in time to recovery, Reduced odds of day 28 mortality. No diff in adverse events, with slightly higher bacterial infections (not stats sig).
